US equities |
MU $1,080.59 ▲+3.35% NVDA $237.09 ▼-0.90% SNDK $1,701.06 ▲+2.45% SPCX $167.77 ▼-2.41% AMD $642.80 ▼-1.02% TSLA $377.68 ▼-0.79% INTC $112.56 ▲+0.05% AAPL $336.99 ▲+1.01%
FinancialContent

Savara, Inc. - Common Stock (NQ:SVRA)

4.885 +0.235 (+5.05%)
Delayed Quote Updated: 3:25 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Savara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Top movers in Tuesday's after hours session ↗
Via Chartmill
News headline image
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
From Savara Inc.
Via Business Wire
News headline image
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline ↗
This clinical-stage biotech focused on rare lung diseases reported significant insider selling amid a year of strong share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Chief Financial and Administrative Officer Transition
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. 
Via The Motley Fool
News headline image
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
From Savara Inc.
Via Business Wire
News headline image
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Reports First Quarter Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
VR Adviser Adds Over 1 Million Savara Shares ↗
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in 2026 Citizens Life Sciences Conference
From Savara Inc.
Via Business Wire
News headline image
SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy ↗
The company is seeking approval for Molbreevi to treat patients with Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP). 
Via Stocktwits
Topics Intellectual Property Lawsuit
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >